The results indicate that, in a statistically significant manner, SLC9A2 expression levels serve as a favorable prognostic factor for CRC patients, including overall survival (OS), recurrence-free survival (RFS), disease-specific survival (DSS), and progression-free survival (PFS) (Fig. 2A). This evidence concerns the gene SLC9A2 and colorectal carcinoma.